.After a handful of years in biotech, Mike Quigley, Ph.D., is coming back to the pharma layer, using up the leading scientific research area at Sanofi.Quigley will certainly start Sept. 30 as the French Big Pharma’s chief scientific policeman as well as global chief of research study, Sanofi said to Fierce Biotech in an emailed declaration.Quigley is replacing Frank Nestle, M.D., that left behind Sanofi this spring amidst a worldwide overhaul of the provider’s R&D unit. Nestle, who invested 8 years with the pharma, dove over to Deerfield Monitoring, where he presently serves as a partner on the therapeutics team as well as CEO of the agency’s therapeutic discovery and progression functions.
Quigley is going to participate in Sanofi from a San Francisco-based biotech that resides in stealth, according to his LinkedIn account. He is actually currently specified as the provider’s founder, head of state and also chief executive officer.Given that August 2021, Quigley has served as a project companion at SV Health and wellness Investors, a healthcare fund manager along with present assets in biotechs including BioAge, Cerevance, Dualitas Rehabs and also Nimbus Rehabs, among others. Quigley in the past stored the leading place at Dualitas, a biotech that remains in stealth, according to STAT.The future Sanofi innovator additionally earlier helmed Therini Biography, an immunotherapy biotech operating to develop procedures for neurodegenerative diseases driven by vascular disorder.Just before spending the last handful of years in biotech, Quigley has an even longer record in Big Pharma, most recently acting as Gilead’s senior bad habit head of state of analysis the field of biology till the summer months of 2021.
Before that, he clocked in much more than four years all over numerous management tasks at Bristol Myers Squibb and also worked as a scientific director at Johnson & Johnson’s Janssen arm before that.Sanofi claimed Quigley’s goal in his brand new part would certainly be to “optimize our likelihood of success through optimal collaborations around our organization and also beyond, bringing best-in-class innovation and also establishing as well as sourcing brand-new industry-leading skill with a devotion to variety,” according to an internal memo secured through STAT.